A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.

A composition for use as antioxidant, where the composition has at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an amino acid salt of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). The anthocyanin component is cyanidin-3-glucoside, delphinidin-3-glucoside, malvidin-3-galactoside, peonidin-3-galactoside, or malvidin-3-glucoside. A method for treating a disease with the composition. A method of providing an antioxidant to a subject with the composition.

The present invention provides a new system with emerging properties in the form of a mixture or composition and the use of the same in the treatment or in assisting the treatment of the metabolic syndrome or one or more symptoms related to it.

The present invention provides a new system with emerging properties in the form of a mixture or composition and the use of the same in the treatment or in assisting the treatment of the metabolic syndrome or one or more symptoms related to it.

The present invention relates to new compositions for the oral administration of apolipoproteins in the dimeric or multimeric form, with specific dosage regimens for use in the treatment of atherosclerosis.

##STR00001##

A compound having the formula (1), (2), (3) or (4), or combinations thereof, for use in the treatment or prevention of cardiovascular disorders in a subject, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently, a long chain fatty acid having between 16 and 20 carbons.

##STR00001##

A compound having the formula (1), (2), (3) or (4), or combinations thereof, for use in the treatment or prevention of cardiovascular disorders in a subject, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are independently, a long chain fatty acid having between 16 and 20 carbons.

A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

The present disclosure relates to a bioavailable, oil composition wherein at least 20% by weight % of its total lipids content comprises polar lipids such as glycolipids or phospholipids, at least 30 weight % of its polar lipids comprises glycolipids, and no more than 4% by weight % of the oil composition is made up of chlorophyll species. Formulations containing and methods for producing said oil compositions from algal oils or extracts are also disclosed.